30 years and a long way into p53 research

The Lancet Oncology

Volumn 10, Issue 9, 2009, Pages 913-919

  Hainaut, Pierre ^a   Wiman, Klas G ^b  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; PROTEIN P53;

AMINO TERMINAL SEQUENCE; CANCER CELL; CANCER GENETICS; CANCER PREVENTION; CANCER STAGING; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL TRANSFORMATION; CLINICAL TRIAL; DISEASE COURSE; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DNA VIRUS; GENE EXPRESSION; GENE FUNCTION; GENE INACTIVATION; GENE INTERACTION; GENE MUTATION; GENETIC TRANSFECTION; GENETIC VARIABILITY; HISTORY OF MEDICINE; HUMAN; LEUKEMIA; LEUKEMOGENESIS; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RESEARCH; MOLECULAR BIOLOGY; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; REVIEW; RNA VIRUS; TUMOR SUPPRESSOR GENE; VIRUS GENOME; WILD TYPE;

BIOMEDICAL RESEARCH; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 69149089025     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70198-6     Document Type: Review

References (101)

1. Baker S.J., Fearon E.R., Nigro J.M., et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244 (1989) 217-221
2. Nigro J.M., Baker S.J., Preisinger A.C., et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 342 (1989) 705-708
3. Hall P.A., McKee P.H., Menage H.D., Dover R., and Lane D.P. High levels of p53 protein in UV-irradiated normal human skin. Oncogene 8 (1993) 203-207
4. Kamb A. Cancer: sun protection factor p53. Nature 372 (1994) 730-731
5. Ziegler A., Jonason A.S., Leffell D.J., et al. Sunburn and p53 in the onset of skin cancer. Nature 372 (1994) 773-776
6. Petitjean A., Achatz M.I., Borresen-Dale A.L., Hainaut P., and Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26 (2007) 2157-2165
7. Javier R.T., and Butel J.S. The history of tumor virology. Cancer Res 68 (2008) 7693-7706
8. Stehelin D., Varmus H.E., Bishop J.M., and Vogt P.K. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature 260 (1976) 170-173
9. Tegtmeyer P., Schwartz M., Collins J.K., and Rundell K. Regulation of tumor antigen synthesis by simian virus 40 gene A. J Virol 16 (1975) 168-178
10. Tegtmeyer P., Rundell K., and Collins J.K. Modification of simian virus 40 protein A. J Virol 21 (1977) 647-657
11. Lane D.P., and Crawford L.V. T antigen is bound to a host protein in SV40-transformed cells. Nature 278 (1979) 261-263
12. Linzer D.I., and Levine A.J. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17 (1979) 43-52
13. Kress M., May E., Cassingena R., and May P. Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum. J Virol 31 (1979) 472-483
14. Chang C., Simmons D.T., Martin M.A., and Mora P.T. Identification and partial characterization of new antigens from simian virus 40-transformed mouse cells. J Virol 31 (1979) 463-471
15. DeLeo A.B., Jay G., Appella E., Dubois G.C., Law L.W., and Old L.J. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci USA 76 (1979) 2420-2424
16. Rotter V., Witte O.N., Coffman R., and Baltimore D. Abelson murine leukemia virus-induced tumors elicit antibodies against a host cell protein, P50. J Virol 36 (1980) 547-555
17. Sarnow P., Ho Y.S., Williams J., and Levine A.J. Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell 28 (1982) 387-394
18. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., and Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63 (1990) 1129-1136
19. Werness B.A., Levine A.J., and Howley P.M. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248 (1990) 76-79
20. Jenkins J.R., Rudge K., Redmond S., and Wade-Evans A. Cloning and expression analysis of full length mouse cDNA sequences encoding the transformation associated protein p53. Nucleic Acids Res 12 (1984) 5609-5626
21. Eliyahu D., Raz A., Gruss P., Givol D., and Oren M. Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature 312 (1984) 646-649
22. Jenkins J.R., Rudge K., and Currie G.A. Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53. Nature 312 (1984) 651-654
23. Jenkins J.R., Rudge K., Chumakov P., and Currie G.A. The cellular oncogene p53 can be activated by mutagenesis. Nature 317 (1985) 816-818
24. Milner J. Different forms of p53 detected by monoclonal antibodies in non-dividing and dividing lymphocytes. Nature 310 (1984) 143-145
25. Maltzman W., and Czyzyk L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol 4 (1984) 1689-1694
26. Mowat M., Cheng A., Kimura N., Bernstein A., and Benchimol S. Rearrangements of the cellular p53 gene in erythroleukaemic cells transformed by Friend virus. Nature 314 (1985) 633-636
27. Eliyahu D., Michalovitz D., Eliyahu S., Pinhasi-Kimhi O., and Oren M. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci USA 86 (1989) 8763-8767
28. Finlay C.A., Hinds P.W., and Levine A.J. The p53 proto-oncogene can act as a suppressor of transformation. Cell 57 (1989) 1083-1093
29. Hollstein M., Sidransky D., Vogelstein B., and Harris C.C. p53 mutations in human cancers. Science 253 (1991) 49-53
30. Malkin D., Li F.P., Strong L.C., et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250 (1990) 1233-1238
31. Srivastava S., Zou Z.Q., Pirollo K., Blattner W., and Chang E.H. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348 (1990) 747-749
32. Oren M. p53: the ultimate tumor suppressor gene?. FASEB J 6 (1992) 3169-3176
33. Kastan M.B., Zhan Q., el-Deiry W.S., et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71 (1992) 587-597
34. Lane D.P. Cancer: p53, guardian of the genome. Nature 358 (1992) 15-16
35. Lowe S.W., Schmitt E.M., Smith S.W., Osborne B.A., and Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362 (1993) 847-849
36. Lowe S.W., Ruley H.E., Jacks T., and Housman D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74 (1993) 957-967
37. Yonish-Rouach E., Resnitzky D., Lotem J., Sachs L., Kimchi A., and Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352 (1991) 345-347
38. Donehower L.A., Harvey M., Slagle B.L., et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356 (1992) 215-221
39. Kern S.E., Kinzler K.W., Bruskin A., et al. Identification of p53 as a sequence-specific DNA-binding protein. Science 252 (1991) 1708-1711
40. Funk W.D., Pak D.T., Karas R.H., Wright W.E., and Shay J.W. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol 12 (1992) 2866-2871
41. el-Deiry W.S., Kern S.E., Pietenpol J.A., Kinzler K.W., and Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1 (1992) 45-49
42. Zambetti G.P., Bargonetti J., Walker K., Prives C., and Levine A.J. Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev 6 (1992) 1143-1152
43. Farmer G., Bargonetti J., Zhu H., Friedman P., Prywes R., and Prives C. Wild-type p53 activates transcription in vitro. Nature 358 (1992) 83-86
44. el-Deiry W.S., Tokino T., Velculescu V.E., et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75 (1993) 817-825
45. Barak Y., Juven T., Haffner R., and Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J 12 (1993) 461-468
46. Wu X., Bayle J.H., Olson D., and Levine A.J. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 7 (1993) 1126-1132
47. Koshland Jr. D.E. Molecule of the year. Science 262 (1993) 1953
48. Cho Y., Gorina S., Jeffrey P.D., and Pavletich N.P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265 (1994) 346-355
49. Oliner J.D., Kinzler K.W., Meltzer P.S., George D.L., and Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358 (1992) 80-83
50. Montes de Oca L.R., Wagner D.S., and Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378 (1995) 203-206
51. Jones S.N., Roe A.E., Donehower L.A., and Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378 (1995) 206-208
52. Kubbutat M.H., Jones S.N., and Vousden K.H. Regulation of p53 stability by Mdm2. Nature 387 (1997) 299-303
53. Haupt Y., Maya R., Kazaz A., and Oren M. Mdm2 promotes the rapid degradation of p53. Nature 387 (1997) 296-299
54. Momand J., Zambetti G.P., Olson D.C., George D., and Levine A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69 (1992) 1237-1245
55. Ambs S., Merriam W.G., Bennett W.P., et al. Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. Cancer Res 58 (1998) 334-341
56. Pomerantz J., Schreiber-Agus N., Liegeois N.J., et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92 (1998) 713-723
57. Kamijo T., Weber J.D., Zambetti G., Zindy F., Roussel M.F., and Sherr C.J. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 95 (1998) 8292-8297
58. Siliciano J.D., Canman C.E., Taya Y., Sakaguchi K., Appella E., and Kastan M.B. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev 11 (1997) 3471-3481
59. Canman C.E., Lim D.S., Cimprich K.A., et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281 (1998) 1677-1679
60. Shieh S.Y., Ahn J., Tamai K., Taya Y., and Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 14 (2000) 289-300
61. Zindy F., Eischen C.M., Randle D.H., et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12 (1998) 2424-2433
62. Kaghad M., Bonnet H., Yang A., et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90 (1997) 809-819
63. Schmale H., and Bamberger C. A novel protein with strong homology to the tumor suppressor p53. Oncogene 15 (1997) 1363-1367
64. Yang A., Kaghad M., Wang Y., et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 2 (1998) 305-316
65. Bourdon J.C., Fernandes K., Murray-Zmijewski F., et al. p53 isoforms can regulate p53 transcriptional activity. Genes Dev 19 (2005) 2122-2137
66. Courtois S., Verhaegh G., North S., et al. DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene 21 (2002) 6722-6728
67. Courtois S., de Fromentel C.C., and Hainaut P. p53 protein variants: structural and functional similarities with p63 and p73 isoforms. Oncogene 23 (2004) 631-638
68. Ghosh A., Stewart D., and Matlashewski G. Regulation of human p53 activity and cell localization by alternative splicing. Mol Cell Biol 24 (2004) 7987-7997
69. Yin Y., Stephen C.W., Luciani M.G., and Fahraeus R. p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products. Nat Cell Biol 4 (2002) 462-467
70. Bykov V.J., Issaeva N., Shilov A., et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 8 (2002) 282-288
71. Foster B.A., Coffey H.A., Morin M.J., and Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science 286 (1999) 2507-2510
72. Vassilev L.T., Vu B.T., Graves B., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303 (2004) 844-848
73. Joerger A.C., Allen M.D., and Fersht A.R. Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations. J Biol Chem 279 (2004) 1291-1296
74. Joerger A.C., Ang H.C., and Fersht A.R. Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc Natl Acad Sci USA 103 (2006) 15056-15061
75. Suad O., Rozenberg H., Brosh R., et al. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations. J Mol Biol 385 (2009) 249-265
76. Marchenko N.D., Zaika A., and Moll U.M. Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J Biol Chem 275 (2000) 16202-16212
77. Bartkova J., Horejsi Z., Koed K., et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434 (2005) 864-870
78. Gorgoulis V.G., Vassiliou L.V., Karakaidos P., et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434 (2005) 907-913
79. Halazonetis T.D., Gorgoulis V.G., and Bartek J. An oncogene-induced DNA damage model for cancer development. Science 319 (2008) 1352-1355
80. Ventura A., Kirsch D.G., McLaughlin M.E., et al. Restoration of p53 function leads to tumour regression in vivo. Nature 445 (2007) 661-665
81. Xue W., Zender L., Miething C., et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445 (2007) 656-660
82. Flores I., and Blasco M.A. A p53-dependent response limits epidermal stem cell functionality and organismal size in mice with short telomeres. PLoS One 4 (2009) e4934
83. Martins C.P., Brown-Swigart L., and Evan G.I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127 (2006) 1323-1334
84. Tyner S.D., Venkatachalam S., Choi J., et al. p53 mutant mice that display early ageing-associated phenotypes. Nature 415 (2002) 45-53
85. Le M.T., Teh C., Shyh-Chang N., et al. MicroRNA-125b is a novel negative regulator of p53. Genes Dev 23 (2009) 862-876
86. Corney D.C., Flesken-Nikitin A., Godwin A.K., Wang W., and Nikitin A.Y. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res 67 (2007) 8433-8438
87. Bommer G.T., Gerin I., Feng Y., et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 17 (2007) 1298-1307
88. He L., He X., Lim L.P., et al. A microRNA component of the p53 tumour suppressor network. Nature 447 (2007) 1130-1134
89. Raver-Shapira N., Marciano E., Meiri E., et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 26 (2007) 731-743
90. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
91. Ory K., Legros Y., Auguin C., and Soussi T. Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J 13 (1994) 3496-3504
92. Lim Y.P., Lim T.T., Chan Y.L., et al. The p53 knowledgebase: an integrated information resource for p53 research. Oncogene 26 (2007) 1517-1521
93. Petitjean A., Mathe E., Kato S., et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28 (2007) 622-629
94. Kato S., Han S.Y., Liu W., et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 100 (2003) 8424-8429
95. Marcel V., and Hainaut P. p53 isoforms-a conspiracy to kidnap p53 tumor suppressor activity?. Cell Mol Life Sci 66 (2009) 391-406
96. Roth J.A., Nguyen D., Lawrence D.D., et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 2 (1996) 985-991
97. Olivier M., Langerod A., Carrieri P., et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 12 (2006) 1157-1167
98. Langerod A., Zhao H., Borgan O., et al. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res 9 (2007) 30
99. Rohaly G., Chemnitz J., Dehde S., et al. A novel human p53 isoform is an essential element of the ATR-intra-S phase checkpoint. Cell 122 (2005) 21-32
100. In: Hainaut P., and Wilman K.G. (Eds). 25 Years of p53 Research. 1st edn. (2005), Springer, Dordrecht
101. In: Hainaut P., and Wilman K.G. (Eds). 25 Years of p53 Research. 2nd edn. (2007), Springer, Dordrecht